文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

伤寒监测、发病率估计及伤寒结合疫苗引入进展——全球,2018-2022年

Typhoid Fever Surveillance, Incidence Estimates, and Progress Toward Typhoid Conjugate Vaccine Introduction - Worldwide, 2018-2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2023-02-17

本报告描述2018-2022年全球伤寒监测、发病率估计和伤寒结合疫苗引入情况。自2018年以来,五个估计伤寒高发病率国家将伤寒结合疫苗纳入常规免疫规划。

要点

  • WHO东南亚区估计发病率最高(306例/10万人),其次为东地中海区(187例/10万人)和非洲区(111例/10万人)。
  • 2018年以来,利比里亚、尼泊尔、巴基斯坦、萨摩亚(基于自评)和津巴布韦五个国家将伤寒结合疫苗纳入常规免疫规划。

核心结论

  • 2018年以来,五个估计伤寒高发病率(≥100例/10万人/年)、抗菌药物耐药高流行或近期暴发的国家将伤寒结合疫苗纳入常规免疫规划。
  • 为指导疫苗引入决策,各国应考虑所有可用信息,包括实验室确诊病例监测、基于人群的研究和建模研究以及暴发报告。
  • 建立和加强伤寒监测对于衡量疫苗影响将很重要。

研究设计与样本

  • 本报告描述2018-2022年全球伤寒监测、发病率估计和伤寒结合疫苗引入状况。
  • 由于伤寒常规监测敏感性低,自2016年以来基于人群的研究指导了10个国家的病例数和发病率估计。
  • 2019年一项更新的建模研究估计了全球伤寒发病和死亡。

主要发现

  • WHO东南亚区估计发病率最高(306例/10万人),其次为东地中海区(187例/10万人)和非洲区(111例/10万人)。
  • 自2018年以来,利比里亚、尼泊尔、巴基斯坦、萨摩亚(基于自评)和津巴布韦五个估计伤寒高发病率(≥100例/10万人/年)、抗菌药物耐药高流行或近期暴发的国家将伤寒结合疫苗纳入常规免疫规划。

关键数值与推荐

  • WHO推荐将伤寒结合疫苗用于伤寒控制,并优先在伤寒发病率最高或抗菌药物耐药伤寒沙门菌高流行的国家引入疫苗。
  • 估计伤寒高发病率定义为≥100例/10万人/年。

临床怎么用

  • 为指导疫苗引入决策,各国应考虑所有可用信息,包括实验室确诊病例监测、基于人群的研究和建模研究以及暴发报告。
  • 建立和加强伤寒监测对于衡量疫苗影响将很重要。

局限性

  • 伤寒常规监测敏感性低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Typhoid fever, an acute febrile illness caused by Salmonella enterica serovar Typhi (S. Typhi), is endemic in many low- and middle-income countries† (1). In 2015, an estimated 11-21 million typhoid fever cases and 148,000-161,000 associated deaths occurred worldwide (2). Effective prevention strategies include improved access to and use of infrastructure supporting safe water, sanitation, and hygiene (WASH); health education; and vaccination (1). The World Health Organization (WHO) recommends programmatic use of typhoid conjugate vaccines for typhoid fever control and prioritization of vaccine introduction in countries with the highest typhoid fever incidence or high prevalence of antimicrobial-resistant S. Typhi (1). This report describes typhoid fever surveillance, incidence estimates, and the status of typhoid conjugate vaccine introduction during 2018-2022. Because routine surveillance for typhoid fever has low sensitivity, population-based studies have guided estimates of case counts and incidence in 10 countries since 2016 (3-6). In 2019, an updated modeling study estimated that 9.2 million (95% CI = 5.9-14.1) typhoid fever cases and 110,000 (95% CI = 53,000-191,000) deaths occurred worldwide, with the highest estimated incidence in the WHO South-East Asian (306 cases per 100,000 persons), Eastern Mediterranean (187), and African (111) regions (7). Since 2018, five countries (Liberia, Nepal, Pakistan, Samoa [based on self-assessment], and Zimbabwe) with estimated high typhoid fever incidence (≥100 cases per 100,000 population per year) (8), high antimicrobial resistance prevalence, or recent outbreaks introduced typhoid conjugate vaccines into their routine immunization programs (2). To guide vaccine introduction decisions, countries should consider all available information, including surveillance of laboratory-confirmed cases, population-based and modeling studies, and outbreak reports. Establishing and strengthening typhoid fever surveillance will be important to measure vaccine impact.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Hancuh M, Walldorf J, Minta AA, et al. Typhoid Fever Surveillance, Incidence Estimates, and Progress Toward Typhoid Conjugate Vaccine Introduction - Worldwide, 2018-2022. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36795626. doi:10.15585/mmwr.mm7207a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。